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by the same method, where a similar 
safety proﬁ  le has been seen after >15 
million vaccinations in humans.
This is the ﬁ  rst study that reports 
that an inactivated whole virus vaccine 
with an aluminum phosphate adjuvant 
system against inﬂ  uenza  A  (H5N1) 
was safe and immunogenic in humans 
after only 1 injection. This study re-
ports the lowest effective dose used 
to cause immune response. Other tri-
als used much higher maximum doses 
and required 2 injections 21 or 28 days 
apart (8–10). Using the lowest possi-
ble amount of the antigen and fewer 
injections is essential for increasing 
the production capacity of vaccine 
manufacturers in a pandemic (2).
Using 1, instead of 2, injections 
will shorten the time needed to devel-
op immune response by 3–4 weeks. 
Unlike previous studies on inﬂ  uenza 
A (H5N1) vaccines that reported only 
data from 21, 28, or 56 days after the 
ﬁ   nal vaccination (8–10), we report 
data up to 90 days. The lower dose 
and fewer injections required to trig-
ger an immune response can be at 
least partially explained by using a 
whole virus vaccine and an aluminum 
phosphate adjuvant system. The use 
of a different adjuvant system than 
ours may have inﬂ  uenced the results 
of other trials (9,10). Other investiga-
tors used a modiﬁ  ed HI method with 
horse erythrocytes, which are known 
to be more sensitive for inﬂ  uenza A 
(H5N1) subtype than the convention-
ally used turkey or chicken erythro-
cytes (8,9). Thus, if horse erythro-
cytes had been used in our study, the 
vaccine would likely have been even 
more immunogenic.
This study found fewer, less fre-
quent, and milder side effects than 
did other trials of inﬂ  uenza A (H5N1) 
vaccines published so far (8–10). 
This could possibly be explained by 
the smaller dose used. Also, the en-
dotoxin content of 0.1 IU/mL in our 
vaccine was much smaller then the 
allowed amount of 100 IU/mL by 
standards (5).
We report an inactivated whole 
virus vaccine that is safe and immu-
nogenic in healthy adults and that re-
quires a low dose and only 1 injection 
to trigger an immune response. We are 
conducting trials in elderly persons 
and children.
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Resistance to 
Dihydroartemisinin
To the Editor: The title of the let-
ter by Cojean et al. (1) is misleading. 
The data presented essentially point to 
an absence of in vitro resistance to di-
hydroartemisinin (dhART) in the pan-
el of African isolates studied, with 1 of 
397 isolates having an elevated 50% 
inhibitory concentration (IC50) for 
dhART. The S769N PfATPase6 muta-
tion associated with in vitro resistance 
to artemether (2) was observed in 1 
isolate. This mutant isolate had a low 
IC50 for dhART, but its IC50 for arte-
mether has not been tested. Since the 
relationship between in vitro suscepti-
bility to artemether and dhART is still 
uncertain (3), these data do not dis-
prove the association of a PfATPase6 
S769N polymorphism with elevated 
IC50 for artemether that was observed 
in isolates from French Guiana (2).
Worth noting is that the associa-
tion of the S769N PfATPase6 poly-
morphism with elevated IC50 for arte-
mether was conﬁ   rmed in an isolate 
collected in French Guiana in 2005; 
that isolate had an IC50 for artemether 
of 127 nmol/L. Molecular typing iden-
tiﬁ  ed 2 clonal types, 1 with a wild-type 
PfATPase6 allele and 1 with a S769N LETTERS
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single mutant. After 3 weeks of in vi-
tro cultivation without drug, the mu-
tant allele was no longer detected and 
the IC50 for artemether was 8.2 nmol/
L. This ﬁ  nding suggests poor ﬁ  tness of 
the mutant allele under standard cul-
ture conditions.
The observation of an additional 
case of in vitro resistance to arte-
mether in French Guiana 3 years after 
the ﬁ  rst cases is of concern. Reinforce-
ment of surveillance is needed as is 
clariﬁ  cation of the relationship of in 
vitro susceptibility to artemether and 
artesunate, the derivatives currently 
included in artemisinin-based combi-
nation therapies (ACTs). Surveillance 
and clariﬁ  cation would be particularly 
timely since emerging clinical or para-
sitologic failures to some ACTs have 
been reported (4,5).
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Resistance to 
Dihydroartemisinin 
In Response: The original title 
of our article was “Lack of Plasmodi-
um falciparum in Vitro and Genomic 
Resistance to Dihydroartemisinin in 
Travelers Returning to France from 
Africa.” EID’s shortening of the title 
(1) led to the perception that the let-
ter title was misleading, but it was not 
on purpose. We have recently tested 
the 50% inhibitory concentration for 
artemether of the S769N PfATPase6 
isolate that we had kept in liquid nitro-
gen, and it showed susceptibility.
We underline that the previous-
ly reported clinical or parasitologic 
failures to some artemisinin-based 
combination therapies (2,3) were not 
synonymous with the emergence of 
resistance to artemisinin compounds. 
In the study by Grandesso et al., a 
combination of artesunate plus amodi-
aquine was given to children <5 years 
of age who lived in an area in which 
amodiaquine alone was ineffective to 
adequately treat uncomplicated falci-
parum malaria in 1 of 3 cases at day 
28 (2). Such a combination (artesunate 
plus amodiaquine) was nearly equiva-
lent in 1 of 3 cases to a 3-day artesu-
nate monotherapy, which may fail to 
completely cure children because of 
the short half-life of artesunate. In 
the study by Bukirwa et al., no recru-
descence occurred in patients treated 
with artesunate plus amodiaquine and 
only 2 of 199 patients treated with 
artemether plus lumefantrine experi-
enced recrudescence at day 28 (3). As 
Birkiwa et al. themselves acknowl-
edged, artemether plus lumefantrine 
was not administered with food, and 
it is known that lumefantrine is ab-
sorbed better when it is taken with a 
small amount of fat. Thus, the clinical 
failures observed did not necessarily 
reﬂ  ect P. falciparum resistance to ar-
temisinin compounds.
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